Cargando…
Secondary acute lymphoblastic leukaemia in a multiple myeloma patient
Secondary acute leukaemia (s-ALL) is a destructive complication in patients who have been previously treated for other cancer. Secondary acute lymphoblastic leukaemia is rarely reported whereas secondary acute myeloid leukaemia is much more common. Chromosomal 11q23 abnormality, frequently detected...
Autores principales: | Piszcz, Jaroslaw, Bolkun, Lukasz, Cichocka, Edyta, Kloczko, Janusz |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Termedia Publishing House
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3687461/ https://www.ncbi.nlm.nih.gov/pubmed/23788951 http://dx.doi.org/10.5114/wo.2012.32497 |
Ejemplares similares
-
The Association between Immune Checkpoint Proteins and Therapy Outcomes in Acute Myeloid Leukaemia Patients
por: Bolkun, Lukasz, et al.
Publicado: (2023) -
To treat or not to treat: metabolomics reveals biomarkers for treatment indication in chronic lymphocytic leukaemia patients
por: Piszcz, Jaroslaw, et al.
Publicado: (2016) -
The role of Interleukin-17A and Interleukin-17E in multiple myeloma patients
por: Lemancewicz, Dorota, et al.
Publicado: (2012) -
High chymotrypsin-like activity in the plasma of patients with newly diagnosed multiple myeloma treated with bortezomib is predictive of a better response and longer PFS
por: Romaniuk, Wioletta, et al.
Publicado: (2018) -
BAFF and APRIL as TNF superfamily molecules and angiogenesis parallel progression of human multiple myeloma
por: Bolkun, L., et al.
Publicado: (2013)